BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
127.11
-0.08 (-0.06%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 125.46 - 128.74
52 week 55.36 - 133.54
Open 127.00
Vol / Avg. 1.05M/1.18M
Mkt cap 20.59B
P/E     -
Div/yield     -
EPS -1.08
Shares 160.34M
Beta 0.85
Inst. own 99%
Jul 28, 2015
Q2 2015 Biomarin Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 9, 2015
Biomarin Pharmaceutical Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
May 19, 2015
Biomarin Pharmaceutical Inc at UBS Global Healthcare Conference
May 13, 2015
Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Biomarin Pharmaceutical Inc at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Biomarin Pharmaceutical Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Biomarin Pharmaceutical Inc Earnings Release
Mar 3, 2015
Biomarin Pharmaceutical Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -33.21% -17.84%
Operating margin -32.48% -12.46%
EBITD margin - -11.37%
Return on average assets -8.81% -5.66%
Return on average equity -13.70% -9.34%
Employees 1,681 -
CDP Score - -

Address

105 Digital Dr
NOVATO, CA 94949-8703
United States - Map
+1-415-5066700 (Phone)
+1-415-3827889 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. The Company is conducting preclinical development of several other enzyme product candidates for genetic and other metabolic diseases, including BMN-190 for the treatment of late infantile neuronal ceroid lipofuscinosis (LINCL), a form of Batten disease.

Officers and directors

Pierre Lapalme Independent Director
Age: 74
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 60
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Executive Vice President and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller, Chief Accounting Officer
Age: 41
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 64
Bio & Compensation  - Reuters